DR REDDYS LABORATORIES LTD — Call Transcript 2022

Jul 13, 2022

==> picture [440 x 110] intentionally omitted <==

July 13, 2022

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ) BSE Limited (Scrip Code: 500124)

Dear Sirs,

Sub: Earnings Call Notification

Please find enclosed a notification titled “Dr. Reddy's to release Q1 FY 23 results on July 28th, 2022 Earnings call slated for July 28th @ 6:30 PM IST / 9:00 AM EDT”

This is for your information.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

KUMAR Digitally signed by KUMAR RANDHIR RANDHIR SINGH Date: 2022.07.13 SINGH 22:40:41 +05'30' K Randhir Singh

Company Secretary & Compliance Officer

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd.

Press Release

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500034, Telangana, India.

CONTACT INVESTOR RELATIONS MEDIA RELATIONS AMIT AGARWAL USHA IYER amita@drreddys.com ushaiyer@drreddys.com

………………………………………………………………………………………………………………………..……………….

Dr. Reddy's to release Q1 FY 23 results on July 28[th] , 2022 Earnings call slated for July 28[th] @ 6:30 PM IST / 9:00 AM EDT

Hyderabad, India, July 13[th] , 2022

……………………………………………………………………………………………………………………………………………………………………...

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the first quarter ended June 30[th] , 2022 on Thursday, July 28[th] , 2022 after the Board Meeting.

Summary of Events

	Event	Date and Time	Medium
	Release of financial results	July 28th, after the Board Meeting	Stock Exchange, Media, Companywebsite, Business wire, Email
	Press meet presentation	Will be available on the Company’swebsite	Company’s websitewww.drreddys.com
	Earnings Call	July 28th, 6:30 PM IST / 9:00 AM EDT	Hosted by the Company(Details below)
	Playback of Earnings Call	After the earnings call till August 3rd,2022	Details below
	Transcript of the Earnings call	Will be available on the Company’swebsite	Company’s websitewww.drreddys.com

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Play Back

The play back will be available after the earnings call, till August 3[rd] , 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 96436.

KUMAR RANDH Digitally signed by KUMAR RANDHIR SINGH IR Date: 2022.07.13 22:41:30 +05'30' SINGH

Conference Joining Information

Option 1: Express Join with DiamondPass™

Pre-register with the below link and join without waiting for the operator.

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3962534&linkSecurityString=119134f0e6

Option 2: Join through below Dial-In Numbers

	Universal Access Number:	+91 22 6280 1219
		+91 22 7115 8120
		USA:1 866 746 2133
	International Toll Free Number:	UK:0 808 101 1573Singapore:800 101 2045
		Hong Kong:800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

==> picture [520 x 36] intentionally omitted <==

Digitally KUMAR signed by KUMAR RANDH RANDHIR SINGH IR Date: SINGH 2022.07.13 22:41:44 +05'30'

………………………………………………………………………………………………………………………..……………….

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

……………………………………………………………………………………………………………………………………………………………………..…………………………..… Disclaimer : This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.”

The company assumes no obligation to update any information contained herein.